Top Wall Street Stories: Aduro BioTech, Inc. (NASDAQ:ADRO), Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG), Vicor Corp. (NASDAQ:VICR), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Asta Funding (NASDAQ:ASFI)

Aduro BioTech, Inc. (NASDAQ:ADRO) was downgraded by Zacks from a “hold” rating to a “sell” rating in a report issued on Tuesday. Aduro BioTech, Inc. (NASDAQ:ADRO) belongs to Healthcare sector. Its performance is -7.60%. On last trading day company shares ended up $24.33. Aduro BioTech, Inc. (NASDAQ:ADRO) distance from 50-day simple moving average (SMA50) is -22.14%.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) announced the closing of its previously announced underwritten public offering of 1,176,470 shares of common stock, and warrants to purchase an aggregate of up to 1,176,470 shares of common stock at a combined offering price of $8.50, before underwriting discounts and commissions. The warrants have an exercise price of $10.62 per share, are immediately exercisable, and expire on August 5, 2020. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) shares decreased -13.21% in last trading session and ended the day at $5.65. EYEG return on assets is -715.20%. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) quarterly performance is 32.94%.

Vicor Corp. (NASDAQ:VICR) reported financial results for the second quarter and six months ended June 30, 2015. Revenues for the second quarter ended June 30, 2015 increased to $56,119,000, compared to $53,361,000 for the corresponding period a year ago, but decreased from $64,017,000 for the first quarter of 2015. Second quarter bookings decreased to $48,096,000 from $57,579,000 for the corresponding period a year ago, and decreased from $59,541,000 for the first quarter of 2015.On 05 August, Vicor Corp. (NASDAQ:VICR) shares moved up 3.36% and was closed at $10.77. VICR EPS growth in last 5 year was -48.20%. Vicor Corp. (NASDAQ:VICR) year to date (YTD) performance is -10.99%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) said that, it will release second quarter 2015 financial results on Monday, August 10, 2015 after the U.S. financial markets close. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares advanced 1.12% in last trading session and ended the day at $23.56. CLDX return on assets is -48.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -4.23%.

Asta Funding Inc. (NASDAQ:ASFI) said that, it will report its financial results for the third quarter and nine months of fiscal year 2015, the period ended June 30, 2015 before the markets open on Monday, August 10, 2015.Asta Funding Inc. (NASDAQ:ASFI) shares moved up 0.12% in last trading session and ended the day at $8.35. ASFI Gross Margin is 97.10% and its return on assets is 2.80%. Asta Funding Inc. (NASDAQ:ASFI) quarterly performance is -0.60%.

Leave a Reply

Your email address will not be published. Required fields are marked *